TOSO, also known as Fas-inhibitory molecule 3 (FAIM3) or Fc mu receptor (FCMR) in humans is encoded by the FCMR gene. FCMR
was defined as a 60-kD transmembrane sialoglycoprotein and FCMR (TOSO) expression was up-regulated on B cells, but was down-modulated on T cells, suggesting differential regulation of TOSO expression during B and T cell activation. Human FCMR mRNA was strongly
expressed in hematopoietic tissues such as the spleen, thymus and peripheral blood leukocytes. Intracellular upregulation of Fc mu receptor (FCMR, FAIM3/TOSO) gene in the leukemic lymphocytes of the patients with CLL may be an important parameter in predicting the progression of the disease.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE